The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme
about
Structural basis of peptide recognition by the angiotensin-1 converting enzyme homologue AnCE from Drosophila melanogasterA modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzymeAbeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzymeAngiotensin-I-converting enzyme and its relativesThe Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-AnalysisRediscovering ACE: novel insights into the many roles of the angiotensin-converting enzymeN-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetesThe N Domain of Human Angiotensin-I-converting Enzyme: THE ROLE OF N-GLYCOSYLATION AND THE CRYSTAL STRUCTURE IN COMPLEX WITH AN N DOMAIN-SPECIFIC PHOSPHINIC INHIBITOR, RXP407Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptideMolecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptidesFragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitorsCrystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzymeLong-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertensionA new antifibrotic target of Ac-SDKP: inhibition of myofibroblast differentiation in rat lung with silicosisAngiotensin-converting enzyme is a modifier of hypertensive end organ damageExpression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cellsRXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.Inhibitory effect of reactive oxygen species on angiotensin I-converting enzyme (kininase II).The use of Fluorescence Resonance Energy Transfer (FRET) peptides for measurement of clinically important proteolytic enzymes.N- versus C-domain selectivity of catalytic inactivation of human angiotensin converting enzyme by lisinopril-coupled transition metal chelatesAngiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury.ACE for all - a molecular perspectiveAce revisited: a new target for structure-based drug design.MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibitionAngiotensin-converting enzymes and drug discovery in cardiovascular diseases.Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE).A novel angiotensin I-converting enzyme mutation (S333W) impairs N-domain enzymatic cleavage of the anti-fibrotic peptide, AcSDKP.A story of two ACEs.Angiotensin I-converting enzyme and potential substrates in human testis and testicular tumours.Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity.Nontraditional roles of angiotensin-converting enzyme.Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats.The hematopoietic system: a new niche for the renin-angiotensin system.Kinetic and structural characterization of amyloid-β peptide hydrolysis by human angiotensin-1-converting enzyme.Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-prolineAbsence of cell surface expression of human ACE leads to perinatal death.The potential role of milk-derived peptides in cardiovascular disease.Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitorsAntifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design.
P2860
Q24301320-1D938850-3EB8-4783-B456-4B78BAE2431DQ24306614-0B1AFBCC-D851-4148-8241-D44EDCC00C6CQ24317730-3F98D7F2-781B-433D-B227-E16EF780544CQ24796698-2BF5F1DD-2F59-4983-8DB9-DBF4133E2D7BQ26776514-BB3EFD8D-B83B-421C-9B2B-05B3389EE04CQ27004277-75E83D8D-2683-46B6-ACD1-BA232D75A1B6Q27008887-6E3E6585-2C55-4C3F-938E-AE61B66E1DC1Q27664390-D259A8A6-803A-49D8-9F09-E3D19AFFC6D6Q27667064-0FEFB37F-609E-45AF-9296-DA1AD2BB649BQ27674442-A8A2DEA6-C73E-4EC1-BB52-3077CB511B4FQ27679900-99617EC0-05FB-4A6B-8B3E-717D75F983BCQ27680712-2897FA58-E606-429C-95D0-0B2DB3B882FCQ28367770-4126BEBB-4092-4D59-ACDE-599B42C59E14Q28386061-685244AD-9BDC-4F7C-8FC8-012B0537C317Q28505768-4DCC68F4-AB4A-463A-AA2C-DD0753E4B920Q29394497-EC7405AA-77CA-482A-918A-215184BC6081Q30670251-23E24E4B-B15C-4463-AB20-CBD69DE5E440Q32027479-023C3573-E6AA-4FCE-B1FD-AA4694B197DDQ33498973-2A815AD3-F44B-4BA6-9659-DAEBA67FA53CQ33737152-3D027A84-09BF-4C12-BDD2-B78D1BCD1C65Q34086852-E02FF272-1F4B-4C3B-812B-F50930E6AFB8Q34195870-C0DE9B9C-59AA-48F7-9C13-7B9FC13AB50BQ34282839-052D3C4A-4BC6-4F47-8712-15FAB6CB9FE8Q34347713-31C967A6-5C90-4CD3-891E-1C7E4D0302A5Q34423315-C1E2FB54-7A0C-408E-A1E4-9B44A1F8B6EFQ34786191-D5BAC378-1E1B-4B2E-9F85-FEB709D93B16Q35088357-94E039E8-ACB7-4763-855C-6BF60DBC4CCCQ35109747-1DE54B1D-8574-46B0-92BE-E644EC22F525Q35129506-B00A28FC-2A5B-4B4E-AC40-19BC8EF488BAQ35696855-1599529D-5C9A-4B60-9D18-997B11640934Q35836666-60A90A28-197E-49B3-8235-27E678B376BDQ36099917-22CF862B-C3BA-4A23-B907-3822D074B7F6Q36310467-AA444956-E964-4241-B826-C03E1B94D5F7Q36381958-723A73D6-EE7C-47D2-AF96-029C64F3FDC1Q37107046-92A381FF-D70F-4AE6-B0E2-F4A3DF727CEBQ37351830-3D8C06EA-40F5-4407-967A-2A7302E4BD96Q37593031-376FB7CA-CA2F-4347-A597-28E8C0985BF5Q37903711-A35D488F-2FB1-42A5-A7B8-D751922796F3Q37962590-18F8F005-76A6-4E86-B9E0-C99F3730D303Q38076770-99D37653-7744-41F5-9C22-86533973512D
P2860
The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@ast
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@en
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@en-gb
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@nl
type
label
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@ast
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@en
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@en-gb
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@nl
prefLabel
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@ast
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@en
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@en-gb
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@nl
P2093
P3181
P356
P1476
The hemoregulatory peptide N-a ...... angiotensin-converting enzyme
@en
P2093
A Rousseau
M T Chauvet
P304
P3181
P356
10.1074/JBC.270.8.3656
P407
P577
1995-02-24T00:00:00Z